生脉注射液与复方丹参注射液治疗冠心病心绞痛有效性及安全性比较的系统评价

A Systemic Review of Effectiveness and Safety of Shengmai Injection Compared with Compound Danshen Injection in Treating Patients with Coronary Heart Disease Pectoris

目的探讨生脉注射液对比复方丹参注射液治疗冠心病心绞痛的有效性及安全性。方法计算机检索Cochrane图书馆临床对照试验资料库(2011年第1期)、Pubmed(1966年至2011年6月)、Embase(1966年至2011年6月)、中国(CNKI)学术文献总库(1979年至2011年6月)、万方数字化期刊库(1981年至2011年6月)、中文科技期刊数据库(1989年至2011年6月),按纳入与排除标准选择随机对照试验、评价质量,提取资料,并用RevMan4.2软件对数据进行Meta分析。结果共初检出192篇文献,经筛选最终纳入6篇关于生脉注射液对比复方丹参注射液治疗冠心病心绞痛的随机对照研究。以心绞痛为疗效尺度:χ2=6.65,合并OR=3.58,95%CI[1.98,6.46],Z=4.22;以心电图为疗效尺度:χ2=3.05,合并OR=4.52,95%CI[2.84,7.19],Z=6.37。结论生脉注射液对比复方丹参注射液治疗冠心病心绞痛安全有效。

Objective： To approach the effectiveness and safety of Shengmai Injection compared with Compound Danshen Injection in treating patients with coronary heart disease peetoris. Methods： Electronic searches were performed by using the Cochrane central register of controlled trials （Issue1,2011 ）,the Pubmed （1966 to June 2011 ）, the Embase （ 1966 to June 2011 ）, the CNKI （ 1979 to June 2011 ）, the WanFang （1981 to June 2011 ） and the VIP（1989 to June 2011）. Randomized controlled trials （RCTs）were screened the retrieved studies according to predefined inclusion and exclusion criteria. The quality of included studies were evaluated and the RevMan 4.2 software was used formeta analysis. Results： 6 articles of 192 studies were finally included.Therapeutic effect of angina pectoris was selected as the study indices,X^2=6.65,OR=3.58,95%CI [ 1.98,6.46] ,Z=4.22. ECG was se- lected as the study indices,X^2=3.05,OR=4.52,95%CI [2.84,7.19] ,Z=6.37. Conclusion： Danshen Injection is ef- fective and safe to treat elderly patients with coronary heart disease pectoris.